Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Mail Stop G-16, 1600 Clifton Road Atlanta GA, USA.
Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.
The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are essential for treatment and prevention of influenza A and B infections. Oseltamivir resistance among influenza A (H1N1) viruses rapidly emerged and spread globally during the 2007-2008 and 2008-2009 influenza seasons. Approximately 20% and 90% of viruses tested for NAI susceptibility at CDC during these seasons, respectively, were resistant to oseltamivir (IC(50) approximately 100-3000 time>those of sensitive viruses), based on the chemiluminescent NA inhibition assay. Pyrosequencing analysis confirmed H274Y mutation (H275Y in N1 numbering) in the neuraminidase (NA) gene of oseltamivir-resistant viruses. Full NA sequence analysis of a subset of oseltamivir-resistant and sensitive virus isolates from both seasons (n=725) showed that 53 (7.3%) had mutations at residue D151 (D-->E/G/N), while 9 (1.2%) had mutations at Q136 (Q-->K) and 2 (0.3%) had mutations at both residues. Viruses with very high IC(50) for oseltamivir and peramivir, and elevated IC(50) for zanamivir, had H274Y in addition to mutations at D151 and/or Q136, residues which can potentially confer NAI resistance based on recent N1 NA crystal structure data. Mutations at D151 without H274Y, did not elevate IC(50) for any tested NAI, however, Q136K alone significantly reduced susceptibility to zanamivir (36-fold), peramivir (80-fold) and A-315675 (114-fold) but not oseltamivir. Mutations at D151 and Q136 were present only in MDCK grown viruses but not in matching original clinical specimens (n=33) which were available for testing, suggesting that these variants were the result of cell culture selection or they were present in very low proportions. Our findings provide evidence that propagation of influenza virus outside its natural host may lead to selection of virus variants with mutations in the NA that affect sensitivity to NAIs and thus poses implications for drug resistance monitoring and diagnostics.
神经氨酸酶抑制剂(NAIs),奥司他韦和扎那米韦,对于治疗和预防甲型和乙型流感至关重要。在 2007-2008 年和 2008-2009 年流感季节,甲型流感(H1N1)病毒中的奥司他韦耐药性迅速出现并在全球范围内传播。根据化学发光 NA 抑制测定,在美国疾病控制与预防中心(CDC)检测的这两个季节中,分别约有 20%和 90%的病毒对 NAI 敏感性测试呈奥司他韦耐药(IC50 约为敏感病毒的 100-3000 倍)。荧光原位杂交分析证实,奥司他韦耐药病毒的神经氨酸酶(NA)基因中存在 H274Y 突变(N1 编号中的 H275Y)。对这两个季节的奥司他韦耐药和敏感病毒分离株的部分 NA 序列进行全序列分析(n=725)显示,53 株(7.3%)在 D151 残基(D->E/G/N)发生突变,9 株(1.2%)在 Q136 发生突变(Q->K),2 株(0.3%)在两个残基上均发生突变。具有高奥司他韦和帕拉米韦 IC50 值和高扎那米韦 IC50 值的病毒除了在 D151 和/或 Q136 发生突变外,还具有 H274Y 突变,根据最近的 N1 NA 晶体结构数据,这些突变可能导致 NAI 耐药性。没有 H274Y 的 D151 突变不会增加任何测试 NAI 的 IC50 值,但是 Q136K 单独显著降低了对扎那米韦(36 倍)、帕拉米韦(80 倍)和 A-315675(114 倍)的敏感性,但对奥司他韦没有影响。D151 和 Q136 突变仅存在于 MDCK 培养的病毒中,而不存在于可用于检测的匹配原始临床标本(n=33)中,这表明这些变体是细胞培养选择的结果,或者它们存在的比例非常低。我们的研究结果提供了证据,表明流感病毒在其自然宿主之外的传播可能导致具有影响 NAI 敏感性的 NA 突变的病毒变异体的选择,从而对耐药性监测和诊断产生影响。